Cetera Advisor Networks LLC Avadel Pharmaceuticals PLC Transaction History

Cetera Advisor Networks LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$12.55 - $17.22 $120,078 - $164,760	9,568 Added 78.15%	21,811 $368,000
Q4 2023 Feb 13, 2024	BUY	$9.64 - $14.59 $4,347 - $6,580	451 Added 3.82%	12,243 $172,000
Q2 2023 Aug 09, 2023	SELL	$8.48 - $16.48 $7,411 - $14,403	-874 Reduced 6.9%	11,792 $194,000
Q2 2022 Aug 11, 2022	BUY	$1.07 - $6.95 $744 - $4,837	696 Added 5.81%	12,666 $31,000
Q4 2021 Feb 14, 2022	BUY	$7.34 - $11.18 $10,598 - $16,143	1,444 Added 13.72%	11,970 $97,000
Q3 2021 Nov 16, 2021	BUY	$6.49 - $9.91 $68,313 - $104,312	10,526 New	10,526 $103,000

1.07M

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $650M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of Cetera Advisor Networks LLC, based on Form 13F filings with the SEC.

Stay updated on Cetera Advisor Networks LLC with notifications on news.